118 related articles for article (PubMed ID: 30824390)
1. Impact of RAGE polymorphisms on urothelial cell carcinoma clinicopathologic characteristics and long-term survival.
Hung SC; Wang SS; Li JR; Chen CS; Lin CY; Chang LW; Chiu KY; Cheng CL; Ou YC; Yang SF
Urol Oncol; 2019 Sep; 37(9):573.e9-573.e17. PubMed ID: 30824390
[TBL] [Abstract][Full Text] [Related]
2. RAGE gene polymorphism and environmental factor in the risk of oral cancer.
Su S; Chien M; Lin C; Chen M; Yang S
J Dent Res; 2015 Mar; 94(3):403-11. PubMed ID: 25582438
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms in the receptor for advanced glycation end-products (RAGE) gene and circulating RAGE levels as a susceptibility factor for non-alcoholic steatohepatitis (NASH).
Mehta R; Shaw G; Masschelin P; Felix S; Otgonsuren M; Baranova A; Goodman Z; Younossi Z
PLoS One; 2018; 13(6):e0199294. PubMed ID: 29928018
[TBL] [Abstract][Full Text] [Related]
4. Effects of RAGE Gene Polymorphisms on the Risk and Progression of Hepatocellular Carcinoma.
Su SC; Hsieh MJ; Chou YE; Fan WL; Yeh CB; Yang SF
Medicine (Baltimore); 2015 Aug; 94(34):e1396. PubMed ID: 26313784
[TBL] [Abstract][Full Text] [Related]
5. Impacts of CA9 gene polymorphisms on urothelial cell carcinoma susceptibility and clinicopathologic characteristics in Taiwan.
Wang SS; Liu YF; Ou YC; Chen CS; Li JR; Yang SF
PLoS One; 2013; 8(12):e82804. PubMed ID: 24349364
[TBL] [Abstract][Full Text] [Related]
6. The promoter polymorphisms of receptor for advanced glycation end products were associated with the susceptibility and progression of sepsis.
Shao Y; Shao X; He J; Cai Y; Zhao J; Chen F; Tao H; Yin Z; Tan X; He Y; Lin Y; Li K; Cui L
Clin Genet; 2017 Apr; 91(4):564-575. PubMed ID: 27172264
[TBL] [Abstract][Full Text] [Related]
7. Functional genetic variant of WW domain containing oxidoreductase gene associated with urothelial cell carcinoma clinicopathologic characteristics and long-term survival.
Hung SC; Chou YE; Li JR; Chen CS; Lin CY; Chang LW; Chiu KY; Cheng CL; Ou YC; Wang SS; Yang SF
Urol Oncol; 2020 Feb; 38(2):41.e1-41.e9. PubMed ID: 31474505
[TBL] [Abstract][Full Text] [Related]
8. Impact of Matrix Metalloproteinases 11 Gene Variants on Urothelial Cell Carcinoma Development and Clinical Characteristics.
Li CC; Hsieh MJ; Wang SS; Hung SC; Lin CY; Kuo CW; Yang SF; Chou YE
Int J Environ Res Public Health; 2020 Jan; 17(2):. PubMed ID: 31940762
[TBL] [Abstract][Full Text] [Related]
9. Effect of
Hung SC; Wang SS; Li JR; Chen CS; Yang CK; Chiu KY; Cheng CL; Ou YC; Ho HC; Yang SF
Int J Med Sci; 2018; 15(14):1731-1736. PubMed ID: 30588197
[TBL] [Abstract][Full Text] [Related]
10. Association of
Hu D; Liu Q; Lin X; Zhang H; Lin J; Zheng X; Peng F
J Cancer; 2019; 10(2):504-509. PubMed ID: 30719146
[No Abstract] [Full Text] [Related]
11. Dopamine receptor D2 genetic variations is associated with the risk and clinicopathological variables of urothelial cell carcinoma in a Taiwanese population.
Tung MC; Wen YC; Wang SS; Lin YW; Liu YC; Yang SF; Chien MH
Int J Med Sci; 2018; 15(11):1187-1193. PubMed ID: 30123056
[TBL] [Abstract][Full Text] [Related]
12. Effects of Long Noncoding RNA H19 Polymorphisms on Urothelial Cell Carcinoma Development.
Yang PJ; Hsieh MJ; Hung TW; Wang SS; Chen SC; Lee MC; Yang SF; Chou YE
Int J Environ Res Public Health; 2019 Apr; 16(8):. PubMed ID: 31013794
[TBL] [Abstract][Full Text] [Related]
13. Determination of
Uloza V; Tamauskaite T; Vilkeviciute A; Pasvenskaite A; Liutkevicius V; Liutkeviciene R
Dis Markers; 2019; 2019():3907232. PubMed ID: 31781300
[TBL] [Abstract][Full Text] [Related]
14. Impact of endothelial nitric oxide synthase polymorphisms on urothelial cell carcinoma development.
Tsay MD; Hsieh MJ; Wang SS; Wang WC; Chou YY; Shih CH; Yang SF; Chou YE
Urol Oncol; 2019 Apr; 37(4):293.e1-293.e9. PubMed ID: 30611644
[TBL] [Abstract][Full Text] [Related]
15. WISP1 genetic variants as predictors of tumor development with urothelial cell carcinoma.
Lee HL; Chiou HL; Wang SS; Hung SC; Chou MC; Yang SF; Hsieh MJ; Chou YE
Urol Oncol; 2018 Apr; 36(4):160.e15-160.e21. PubMed ID: 29277583
[TBL] [Abstract][Full Text] [Related]
16. Genetic predisposition of six well-defined polymorphisms in HMGB1/RAGE pathway to breast cancer in a large Han Chinese population.
Yue L; Zhang Q; He L; Zhang M; Dong J; Zhao D; Ma H; Pan H; Zheng L
J Cell Mol Med; 2016 Oct; 20(10):1966-73. PubMed ID: 27241711
[TBL] [Abstract][Full Text] [Related]
17. The impact of receptor of advanced glycation end-products polymorphisms on prostate cancer progression and clinicopathological characteristics.
Chou YE; Hsieh MJ; Wang SS; Lin CY; Chen YY; Ho YC; Yang SF
J Cell Mol Med; 2021 Nov; 25(22):10761-10769. PubMed ID: 34708514
[TBL] [Abstract][Full Text] [Related]
18. Impact of EZH2 polymorphisms on urothelial cell carcinoma susceptibility and clinicopathologic features.
Yu YL; Su KJ; Hsieh MJ; Wang SS; Wang PH; Weng WC; Yang SF
PLoS One; 2014; 9(4):e93635. PubMed ID: 24691023
[TBL] [Abstract][Full Text] [Related]
19. The Association Between Variants of Receptor for Advanced Glycation End Products (RAGE) Gene Polymorphisms and Age-Related Macular Degeneration.
Banevicius M; Vilkeviciute A; Kriauciuniene L; Liutkeviciene R; Deltuva VP
Med Sci Monit; 2018 Jan; 24():190-199. PubMed ID: 29317590
[TBL] [Abstract][Full Text] [Related]
20. A multicenter matched case-control analysis on seven polymorphisms from HMGB1 and RAGE genes in predicting hepatocellular carcinoma risk.
Wang D; Qi X; Liu F; Yang C; Jiang W; Wei X; Li X; Mi J; Tian G
Oncotarget; 2017 Jul; 8(30):50109-50116. PubMed ID: 28187002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
